- Home
- ABSI vs PACB Comparison
ABSI vs PACB Comparison
Compare ABSI & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- PACB
- Stock Information
- Founded
- ABSI 2011
- PACB 2000
- Country
- ABSI United States
- PACB United States
- Employees
- ABSI N/A
- PACB N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- PACB Biotechnology: Laboratory Analytical Instruments
- Sector
- ABSI Health Care
- PACB Industrials
- Exchange
- ABSI Nasdaq
- PACB Nasdaq
- Market Cap
- ABSI 353.8M
- PACB 364.2M
- IPO Year
- ABSI 2021
- PACB 2010
- Fundamental
- Price
- ABSI $2.65
- PACB $0.96
- Analyst Decision
- ABSI Strong Buy
- PACB Buy
- Analyst Count
- ABSI 5
- PACB 9
- Target Price
- ABSI $8.40
- PACB $2.34
- AVG Volume (30 Days)
- ABSI 2.9M
- PACB 9.9M
- Earning Date
- ABSI 05-13-2025
- PACB 05-08-2025
- Dividend Yield
- ABSI N/A
- PACB N/A
- EPS Growth
- ABSI N/A
- PACB N/A
- EPS
- ABSI N/A
- PACB N/A
- Revenue
- ABSI $4,815,000.00
- PACB $152,357,000.00
- Revenue This Year
- ABSI $145.79
- PACB $4.67
- Revenue Next Year
- ABSI $99.29
- PACB $19.09
- P/E Ratio
- ABSI N/A
- PACB N/A
- Revenue Growth
- ABSI N/A
- PACB N/A
- 52 Week Low
- ABSI $2.01
- PACB $0.85
- 52 Week High
- ABSI $6.33
- PACB $2.72
- Technical
- Relative Strength Index (RSI)
- ABSI 40.44
- PACB 41.28
- Support Level
- ABSI $2.56
- PACB $0.85
- Resistance Level
- ABSI $2.84
- PACB $1.15
- Average True Range (ATR)
- ABSI 0.20
- PACB 0.09
- MACD
- ABSI -0.01
- PACB 0.00
- Stochastic Oscillator
- ABSI 8.26
- PACB 34.45
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.